Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and maintained a $15 price target for the company's stock.
January 17, 2024 | 11:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Recursion Pharmaceuticals with a maintained price target of $15, indicating a positive outlook for the stock.
The reiteration of a Buy rating by a reputable analyst like Gil Blum from Needham tends to instill confidence in investors and can lead to a positive short term impact on the stock price. The maintenance of the $15 price target suggests that the analyst's valuation of the company remains unchanged and optimistic.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100